Royal Marsden NHS Foundation Trust

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Activity

Recent Activity

Last 14 days

Oct 30, 2026

Recruiting

Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer

Oct 29, 2026

Recruiting

Short-course Hypofractionated Online-adaptive Radiotherapy for the Treatment of ENdometrial Cancer

Oct 28, 2026

Completed

A Phase I Trial of VS-6766 (RO5126766) (a Dual RAF/MEK Inhibitor) Exploring Intermittent, Oral Dosing Regimens in Patients With Solid Tumours or Multiple Myeloma, With an Expansion to Explore Intermittent Dosing in Combination With Everolimus

Earlier

Oct 17, 2026TrialProstate Cancer Retrospective Prevalence, Screening, Outcome Data in NHS-served Prisons UK (PRISON-UK)

Aug 22, 2026TrialPAveMenT: Phase Ib Study of Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

Aug 22, 2026TrialA Randomised Phase II Study of Zimberelimab Anti-PD1 immunOtherapy +/- Domvanalimab Anti-TIGIT Immunotherapy in Resectable Mismatch Repair Deficient Gastric and Gastro-oesophageal Junctional AdenoCarcinoma

Aug 4, 2026TrialExploring the Patient and Provider Perspectives on the Utility of Genetic Risk Profiling for Prostate Cancer in Routine Clinical Practice

Jul 18, 2026TrialStereotactic Body Radiotherapy Radiotherapy With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects

3 more events

Jul 9, 2026TrialA Multi-Centre, Single-Arm Prospective Phase II Clinical Trial of Radiotherapy to the Coeliac Plexus to Help Pain in Advanced Pancreatic Cancer

Jun 30, 2026TrialClinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine: A Tumour Agnostic Study

Mar 11, 2025TrialPreoperative Planning With PSMA-PET in Melanoma Surgery Trial

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)